August 2019

SILVER SPRING, Md. — By 10:30 a.m., a panel of the Food and Drug Administration’s top regulators had already heard from more than 50 different people, all eager to squeeze their hopes or concerns about CBD, the booming marijuana-adjacent compound companies are suddenly adding to everything from dog food to dietary supplements, into the short […]

by

GW Pharmaceuticals‘ Epidiolex, the first plant-derived cannabidiol medication to be approved by the U.S. Food and Drug Administration, is effective in significantly reducing the frequency of epileptic seizures as an adjunct therapy in children with Dravet syndrome and Lennox-Gastaut syndrome, a review study shows. The review, “Epidiolex (Cannabidiol): A New Hope for Patients With Dravet or Lennox-Gastaut […]

by

Some chew it, or place a few drops under the tongue or let it soak in through the skin. There are numerous ways to consume cannabidiol — better known as CBD. It’s touted for its therapeutic effects, but, unlike its better-known cousin THC, does not get you high. Hemp-derived CBD is increasingly in the limelight […]

by

Some chew it, or place a few drops under the tongue or let it soak in through the skin. There are numerous ways to consume cannabidiol — better known as CBD. It’s touted for its therapeutic effects, but, unlike its better-known cousin THC, does not get you high. Hemp-derived CBD is increasingly in the limelight […]

by

SG Americas Securities LLC purchased a new stake in Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) during the 2nd quarter, according to the company in its most recent filing with the Securities Exchange Commission. The fund purchased 15,473 shares of the company’s stock, valued at approximately $210,000. SG Americas Securities LLC owned approximately 0.07% of Zynerba Pharmaceuticals as […]

by

Millendo Therapeutics (NASDAQ:MLND) and Zynerba Pharmaceuticals (NASDAQ:ZYNE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability. Risk and Volatility Millendo Therapeutics has a beta of 2.64, suggesting that its share price […]

by

A preclinical study has shown that a new dual-targeting APRIL CAR T-cell therapy appears to be better at eliminating multiple myeloma cells than conventional CAR T-cell therapies. The findings were reported in a study titled, “An APRIL based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma has potent activity in vitro and […]

by

SG Americas Securities LLC acquired a new stake in shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 15,473 shares of the company’s stock, valued at approximately $210,000. Other large investors also recently made changes to their positions in […]

by

SAN FRANCISCO and TEL AVIV, Israel, Aug. 29, 2019 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera“) today reported financial results for the second quarter of 2019. (All dollars U.S. unless otherwise noted.) “Kalytera made important progress in its lead product development program during the second quarter. […]

by

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/drugs-in-the-pipeline/apb-102-receives-orphan-drug-designation-for-genetic-sod1-als/

by